Drugs and Medicines

Frontline Cancer: Some cancers may be suitable targets of iPSC-derived NK cells

Frontline Cancer: Some cancers may be suitable targets of iPSC-derived NK cells

FRONTLINE CANCER:

In recent years, CAR-T cell-based immunotherapies have grabbed headlines, taking off like, well, a race car. Broadly speaking, these treatments are based on the idea that the body's own immune system is best-suited to fighting cancer — something it does every day to great effect in most people — but that sometimes it can use extra help.

Until recently, cancer treatments have been relatively blunt-force remedies that do not adequately differentiate between healthy and malignant cells. They often sacrificed normal tissues in the effort to kill cancerous cells, resulting in temporary but often harsh side effects and long-term unwanted...

65°